Skip to main content
Black Health logo Black Health

Sickle Cell · New York

Sickle cell disease resources in New York

SCDAA chapter Medicaid: CRISPR covered NHLBI SCDIC state ~10,200 SCD patients

SCDAA chapter

Sickle Cell Thalassemia Patients Network (NYC)

Visit chapter site 1-718-826-2775

New York was the first state in the U.S. to add sickle cell screening to its universal newborn screening panel (1975). The Children's Hospital at Montefiore, Mount Sinai Adult SCD program, NYU Langone, and Columbia Presbyterian / NewYork-Presbyterian together form one of the densest SCD care networks in the country. New York Medicaid issued written Casgevy / Lyfgenia policy in 2024.

Roughly 10,200 people in New York are estimated to live with sickle cell disease; the figure comes from the CDC's Sickle Cell Data Collection program in participating states and from NHLBI modeling elsewhere. New York began universal newborn screening for sickle cell disease in 1975 — every baby born in the state is now screened at birth, which lets families start twice-daily penicillin prophylaxis by two months old and dramatically reduces childhood SCD mortality. For confirmatory testing and hematology follow-up after a positive screen, ask your pediatrician for a referral to the closest comprehensive sickle cell center listed on this page.

New York Medicaid covers hydroxyurea — the cornerstone disease-modifying therapy for SCD. New York Medicaid published written coverage policy for Casgevy (exa-cel) and Lyfgenia (lovo-cel) in 2024. As of 2026, only roughly 45 comprehensive centers nationally are authorized to administer Casgevy (exa-cel), and fewer still are authorized for Lyfgenia (lovo-cel). Coverage status alone doesn't guarantee access — patients must be at least 12 years old with recurrent vaso-occlusive crises, enrolled at an authorized center, and cleared through the center's multi-step stem-cell-collection and conditioning protocol.

Community support in New York runs through Sickle Cell Thalassemia Patients Network (NYC). SCDAA chapters coordinate annual Sickle Cell Awareness events, patient education, and advocacy — most keep a current list of pediatric and adult comprehensive clinics in the state and can help patients navigate insurance pre-authorization for disease-modifying therapies.

New York at a glance

Newborn screening start
1975
Estimated SCD patients in state
~10,200
Medicaid: hydroxyurea
Covered
Medicaid: CRISPR gene therapy
Covered (written policy published)

Comprehensive care centers in New York

Children's Hospital at Montefiore Sickle Cell Program

Bronx, NY

Pediatric Transition

Columbia / NewYork-Presbyterian Adult Sickle Cell Program

New York, NY

Adult Transition CRISPR

Kings County Hospital Center Sickle Cell Program

Brooklyn, NY

Pediatric Adult Transition

Mount Sinai Adult Sickle Cell Program

New York, NY

Adult Transition CRISPR

NYU Langone Adult Sickle Cell Clinic

New York, NY

Adult Transition

For Black families

Roughly 1 in every 365 Black infants born in the United States inherits sickle cell disease, and roughly 1 in 13 carries the sickle cell trait — the highest carrier frequency of any population group in the country. Because newborn screening is universal, nearly every Black family in New York whose baby has SCD receives the diagnosis before they leave the hospital — which is exactly why timely follow-up with a comprehensive center matters more than the diagnosis itself.

The hardest periods in the SCD lifespan are the transition from pediatric to adult care (roughly ages 18-25, when preventable mortality peaks) and emergency-department visits for vaso-occlusive crises, where published research has consistently documented longer time-to-analgesia and higher suspicion of drug-seeking behavior for Black SCD patients than for white patients with comparable pain. Transition programs, pain plans, and hematologist letters addressed to ED staff reduce both. Every comprehensive center listed on this page supplies those materials on request.

Where to get help in New York

  • Sickle Cell Thalassemia Patients Network (NYC): https://www.sctpn.org/ · 1-718-826-2775. The state's primary community organization for SCD advocacy, peer support, and family education.
  • Hematology-oncology providers in New York: /providers/?state=NY&specialty=hematology-oncology. Filter our directory to hematology-oncology specialists.
  • Federally Qualified Health Centers in New York: /clinics/ny/. FQHCs accept Medicaid, charge on a sliding scale, and are the practical first stop when you need a primary-care home that will coordinate SCD specialty referrals.
  • New York Medicaid: /medicaid/new-york/ covers eligibility, how to apply, and our new-york tracker for 12-month postpartum extension + doula coverage — relevant to pregnant people carrying sickle cell trait or SCD.
  • CDC Sickle Cell Data Collection program: cdc.gov/ncbddd/hemoglobinopathies/scdc publishes claims-based SCD prevalence for participating states.
  • National SCDAA Connect line: 1-800-421-8453. Routes callers to local chapter resources and hospital social-work teams experienced with SCD.

More on New York

Hematology providers

Hematology-oncology in New York

Filter the provider directory to SCD-treating hematologists.

FQHCs

Federally Qualified Health Centers

Sliding-scale clinics accepting Medicaid.

New York Medicaid

Medicaid coverage in New York

Eligibility, postpartum, doula coverage.

References

  • NHLBI, "Evidence-Based Management of Sickle Cell Disease" (2014 expert panel report): nhlbi.nih.gov.
  • American Society of Hematology 2020 SCD Clinical Practice Guidelines: hematology.org.
  • CDC Sickle Cell Data Collection program: cdc.gov/ncbddd/hemoglobinopathies/scdc.
  • Baby's First Test, state-by-state newborn screening panel: babysfirsttest.org.
  • Sickle Cell Thalassemia Patients Network (NYC): https://www.sctpn.org/.
  • FDA approvals, December 2023: Casgevy (exagamglogene autotemcel, Vertex) + Lyfgenia (lovotibeglogene autotemcel, bluebird bio), CRISPR-based gene therapies for severe SCD.

Data refreshed: